CASUS: Improved and Quality Assured Collection of First-void Urine

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

November 25, 2019

Study Completion Date

November 27, 2019

Conditions
Cervical CancerCervical Intraepithelial NeoplasiaHuman Papilloma VirusHPV-Related Cervical CarcinomaUrine
Interventions
DEVICE

Colli-Pee® (FV5000 and Small Volumes)

"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."

Trial Locations (1)

2610

Centre for the Evaluation of Vaccination (CEV) - Vaccine & Infectious Disease Institute (VAXINFECTIO) - University of Antwerp, Wilrijk

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amsterdam UMC, location VUmc

OTHER

collaborator

Novosanis NV

INDUSTRY

collaborator

Self-screen B.V.

UNKNOWN

lead

Universiteit Antwerpen

OTHER

NCT04480866 - CASUS: Improved and Quality Assured Collection of First-void Urine | Biotech Hunter | Biotech Hunter